Impact of Cannabis and Its Constituents On Lung Functions
=========================================================

Numerous countries have been considering decriminalizing and/or legalizing cannabis use. In that regard, it has become crucial for health agencies to gain a better understanding of how cannabis and its constituents (cannabinoids) impact humans. This article reviews the impact of cannabis consumption on the lungs as well as the impact of the endocannabinoid system in the regulation of lung functions, given that the most popular route of cannabis ingestion is smoking.

The impact of marijuana smoking on structural and immune cells of the lungs has been of interest to researchers for several decades. In 1985, a histological examination of lung tissue sections was done on known marijuana smokers who had died suddenly ([@B42]). The author found macrophage infiltrates in the lungs of marijuana smokers, which were often accompanied by fibrosis with lymphocytes in areas filled with macrophages. Considering the circumstances in which the study was conducted, it was not possible to obtain detailed information about marijuana and tobacco use by these individuals, making it complex to confirm that these cellular changes were caused by marijuana alone. It is now known that cannabis induces effects on lung functions that are not found in tobacco smokers. Although there are marked differences in the composition of marijuana smoke versus tobacco smoke ([@B40]), studies that include groups of non-smokers, marijuana smokers, and tobacco smokers can provide good insight into the role of marijuana and its constituents on the structures and functions of the lungs ([@B49]).

Many studies have described lung damage in marijuana smokers, as well as cellular damages in cells exposed to marijuana smoke or cannabinoids *in cellulo*. [@B21] performed bronchial biopsies on volunteers and found airway hyperemia in both marijuana- and tobacco-smoking groups, as opposed to non-smokers. The authors also observed hyperplasia of goblet and basal cells in both marijuana and tobacco smokers, with a tendency toward higher hyperplasia in marijuana smokers. Of note, cellular disorganization was present in over 50% of marijuana smokers, but was not found in tobacco smokers. However, this type of experimental design still does not provide defined conditions in terms of exposure to cannabis and/or tobacco. In this respect, a study was performed on primates that were exposed to a low or high dose of marijuana, placebo cigarettes or sham smoke ([@B16]). Cannabis exposures were defined as two marijuana cigarettes per week for the low-dose group, and seven marijuana cigarettes per week for the high-dose group. Epithelial hyperplasia was found in all groups, but there was a greater incidence and severity of bronchiolitis, alveolar cell hyperplasia with atypia and fibrosis in marijuana smokers. These findings indicate that cannabis induces some types of cellular damage to the lungs that are not observed with tobacco smoke. Therefore, some bioactive constituents of marijuana (cannabinoids) might be responsible for these effects, suggesting that the endocannabinoid system could also play a role in the regulation of pulmonary health and diseases.

The Cannabinoid Receptors and the Lungs
---------------------------------------

The endocannabinoid system comprises cannabinoid receptors (CB~1~ and CB~2~), their endogenous ligands (endocannabinoids) and the enzymes involved in their metabolism. Some cannabinoids, such as (--)-*trans*- Δ^9^-tetrahydrocannabinol (Δ^9^-THC), can activate the cannabinoid receptors ([@B15]). Others, such as cannabinol and cannabidiol, modulate cell functions through other means ([@B55]; [@B29]; [@B56]). The two best characterized endocannabinoids, namely 2-arachidonoyl-glycerol (2-AG) and arachidonylethanolamide (AEA) also activate cannabinoid receptors. In addition, endocannabinoids activate additional receptors and can be metabolized into other bioactive compounds that can modulate cell functions ([@B65]). In the lungs, the cannabinoid receptors were found on structural cells and most leukocytes.

A study of the distribution of cannabinoid receptors among human organs found both CB~1~ and CB~2~ mRNA in the lungs and the bronchial tissue, with CB~1~ mRNA levels being significantly higher than those of CB~2~ ([@B19]; [@B50]). To this date, there has been no report of the expression of these receptors in primary airway epithelial cells specifically, although the mRNA and protein for both receptors were detected in the 16HBE14o^-^ cell line ([@B20]). Given that airway epithelial cells actively participate in the recognition of pathogens as well as the recruitment of leukocytes in inflammatory conditions ([@B66]), their ability to respond to cannabinoids and endocannabinoids should be further investigated. To our knowledge, there has not been any report of the expression of cannabinoid receptors by human lung fibroblasts.

Among immune cells residing in the airways, alveolar macrophages (AMs) are by far the most numerous, constituting over 90% of the cells recovered by bronchoalveolar lavage ([@B23]). A recent study was performed on human lung-resident macrophages that were isolated from the lung tissue of patients with adenocarcinoma ([@B63]). CB~1~ and CB~2~ mRNA and proteins were detected in both tumor-associated and non-tumor macrophages. CB~2~ levels were higher than those of CB~1~, a pattern that the authors also observed in monocyte-derived macrophages. Interestingly, the cannabinoid receptors expressed in lung macrophages were functional in contrast to those of monocyte-derived macrophages, as assessed by extracellular signal-regulated kinases 1/2 (ERK1/2) phosphorylation assays. This emphasizes the difference between tissue-resident and blood-derived macrophages, as well as the importance of tissue-derived factors in the modulation of macrophage functions. Although they are the most numerous in alveoli, other leukocytes involved in lung immunity also express cannabinoid receptors. Human monocyte-derived dendritic cells (DCs) express both the CB~1~ and CB~2~ receptors, and they also have the ability to synthesize AEA and 2-AG ([@B39]). Both CB receptors were also found in murine bone marrow-derived DCs ([@B14]; [@B38]).

The presence of cannabinoid receptors on circulating leukocytes can also impact lung immunity, as many of these cells are recruited to the lungs at different stages of the inflammatory response. Eosinophils, for example, express large amounts of CB~2~ receptors ([@B47]; [@B10], [@B11]). Monocytes express both cannabinoid receptors, with a predominant expression of CB~2~ ([@B19]; [@B41]; [@B22]; [@B8]). It is less clear whether or not neutrophils express CB~2~, since discrepancies regarding its expression have been reported ([@B19]; [@B33]; [@B11]). A more detailed summary of cannabinoid receptor expression by human leukocytes has recently been reviewed ([@B65]). The role of cannabinoid receptors in modulating the effector functions of these leukocytes is discussed in the next sections.

Impact of Cannabis and Cannabinoids on Structural and Inflammatory Cells Found in the Lungs
-------------------------------------------------------------------------------------------

A limited number of studies investigated the impact of cannabinoids on structural cells found in the lungs. However, Δ^9^-THC changes the expression pattern of numerous genes in primary human airway epithelial cells, notably *PTGS2* and *IL1A*, which encode cyclooxygenase-2 and the proinflammatory cytokine interleukin (IL)-1α, respectively. Moreover, it causes a decrease in cell viability and mitochondrial membrane potential in these cells ([@B57]). Δ^9^-THC also caused mitochondrial damage in the lung epithelial cell line A549 ([@B59]). The use of A549 cells overexpressing the CB~2~ receptor indicated that some of the effects of Δ^9^-THC on the airway epithelium are CB~2~-dependent ([@B58]). As for lung fibroblasts, early *in vitro* studies reported that cannabinoids can stimulate them to synthesize prostaglandin E~2~ ([@B7], [@B6]). However, these experiments were performed in the WI-38 cell line and the involvement of cannabinoid receptors was not elucidated, since these studies were published before they were cloned. To our knowledge, these findings have not been confirmed in primary lung fibroblasts, and the involvement of CB receptors has yet to be determined.

The first line of defense in the lungs against aerosolized bacteria, viruses and toxins consists of resident cells such as bronchial epithelial cells, AMs and DCs. When they encounter a pathogen, they are able recognize it through receptors binding specific molecular motifs found on microorganisms. This triggers signaling events leading to the transcription of pro-inflammatory genes and the release of mediators that induce the recruitment of leukocytes from the circulation. In response to these chemotactic factors, neutrophils are the first cells to be recruited to the lungs. They exert key effector functions and thus, participate in pathogen elimination. Lung homeostasis is restored with the help of AMs that have acquired a pro-resolution, wound-healing phenotype.

Numerous *in cellulo* studies assessed the impact of cannabinoids on human and murine macrophage functions. Experiments performed with mouse peritoneal macrophages demonstrated that Δ^9^-THC downregulates NO (nitric oxide) production in these cells, as well as tumor necrosis factor (TNF)-α maturation and secretion ([@B12]; [@B67]). In RAW264.7 macrophages, the impact of Δ^9^-THC on lipopolysaccharide (LPS)-induced NO production was shown to be a consequence of NF-κB inhibition ([@B24]). The impact of Δ^9^-THC was also investigated in the P388D1 cell line and was shown to impair phagocytic activity of these murine macrophages ([@B64]).

In light of these findings, some have studied the functions of human AMs isolated from healthy volunteers and marijuana smokers and these reports are consistent with the data obtained from murine macrophages. AMs from marijuana smokers were found to have a decreased capability to ingest/kill *Staphylococcus aureus* ([@B3]) and produced less NO following LPS stimulation ([@B61]). This was not the case in AMs recovered from tobacco smokers, indicating that these effects were unlikely to be caused by the smoke itself. The incubation of these AMs with GM-CSF or interferon (IFN)-γ restored their ability to produce NO, suggesting that marijuana exposure causes a decrease in cytokine priming that weakens host defense ([@B54]).

Macrophages and DCs are highly potent antigen presenting cells ([@B32]). DCs constitute a crucial bridge between innate and adaptative immunity. The immature, lung-resident DCs that are located close to the epithelial surface of the respiratory tract can capture and process antigens that enter the lungs. They subsequently migrate to the lymph nodes, where they present the antigen to naïve T cells. Given that they both express cannabinoid receptors, AMs and DCs can respond to exogenous cannabinoids or endocannabinoids, thereby modulating immune responses. In murine cells, Δ^9^-THC was shown to impair LPS-induced bone marrow-derived DC maturation ([@B26]). Moreover, treatment of these DCs with Δ^9^-THC before cultivating them with CD8+ cells reduced their ability to produce IFN-γ, an effect that was dependent on cannabinoid receptors. The CB~2~ receptor was later implicated in the modulation of DC functions, in a study showing that CB~2~ receptor agonists decreased DC migration by reducing matrix metalloproteinase (MMP)-9 production ([@B1]). This cannabinoid-induced decrease in DC migration occurred both *in vivo* and *in vitro*. In *Legionella pneumophila*-infected DCs, Δ^9^-THC treatment impairs Th1 cytokine production, in addition to downregulating the expression of costimulatory molecules as well as major histocompatibility complex II ([@B37]). This effect was later found to involve both cannabinoid receptors ([@B38]). Altogether, these studies point to a detrimental effect of cannabinoids, particularly Δ^9^-THC, on antigen presentation, which impairs the immune response to pulmonary pathogens.

The Endocannabinoid System and the Lungs
========================================

Endocannabinoids are known to regulate immune cell functions, either through cannabinoid receptors or through numerous metabolites ([@B65]). As discussed in Section "The Cannabinoid Receptors and the Lungs," a growing body of evidence indicates that the endocannabinoid system is present in human lungs, with most cell types expressing cannabinoid receptors. Moreover, many structural and immune cells have the ability to synthesize endocannabinoids when exposed to inflammatory stimuli. The impact that this can have on lung homeostasis and disease is not fully understood, and this section discusses the existing *in cellulo* and *in vivo* evidence.

Impact of Endocannabinoids on Structural Cells
----------------------------------------------

Although airway epithelial cells constitute an extremely large contact surface and an important physical barrier, very few studies have investigated the impact of endocannabinoids on their functions, with reports often focusing on immune cells. A recently published study demonstrates that the endocannabinoid AEA increases permeability of the airway epithelial cell line Calu-3 ([@B60]). Of note, this effect was caused by arachidonic metabolites rather than cannabinoid receptor activation. This underscores that airway epithelial cells do not only respond to exogenous cannabinoids, but also have the ability to metabolize endocannabinoids into various bioactive lipid mediators that can modulate immune cell functions. In this respect, Nomura et al. showed that 2-AG is an important source of prostaglandins in the lungs of mice ([@B46]). These findings underscore the importance of 2-AG as a source of arachidonic acid in the lungs, which can also be metabolized by human neutrophils and eosinophils into leukotriene B~4~ and C~4~, respectively ([@B10]; [@B34]).

Impact on Immune Cells
----------------------

### Alveolar Macrophage Functions

To our knowledge, there is currently no evidence of the regulation of human AM functions by endocannabinoids. However, a limited number of studies investigated the impact of 2-AG and AEA on macrophage cell lines. In this regard, AEA, but not 2-AG, was found to impair NO and cytokine production in the J774 murine macrophage cell line ([@B9]). The potentiating effect of 2-AG on NO production was likely caused by its metabolites arachidonic acid and prostaglandin E~2~, as both lipids mimicked this effect. Moreover, there is evidence of J774 macrophages being capable of synthesizing PGD~2~-G and PGE~2~-G, which are COX-2 metabolites of 2-AG ([@B2]). The exogenous addition of PGD~2~-G to J774 cultures downregulated LPS-induced IL-1β production by these cells, whereas the addition of PGE~2~-G or PGF~2α~-G had the opposite effect. Finally, PGD~2~-G reduced LPS-induced inflammation *in vivo*. These findings, in addition to a previous report showing that PGE~2~-G stimulated calcium mobilization in RAW267.4 cells ([@B45]), support that COX-2 metabolites of endocannabinoids regulate macrophage functions, although more research is prompted in order to identify the receptors that mediate these effects. Whether or not these mechanisms translate to human AMs and to lung inflammation also remains to be investigated.

### Leukocyte Recruitment

Leukocyte recruitment to the lungs is a complex process that involves a cellular response to a chemotactic gradient and transmigration through the endothelium. The mechanisms of leukocyte chemotaxis modulation by cannabinoids varies from one cell type to another. Noteworthy, the endocannabinoid 2-AG was shown to exert effects on the endothelium itself, thus promoting Jurkat T cell adhesion and transmigration ([@B58]). These findings should be confirmed using primary human leukocytes in order to clarify the possible role of this mechanism in inflammatory disease.

Despite the conflicting data regarding the expression of CB receptors in neutrophils, the impact of various cannabinoids on neutrophil chemotaxis has been investigated. In one report, the pretreatment of human neutrophils with 2-AG or the CB~2~ agonist JWH015^[1](#fn01){ref-type="fn"}^ impaired their chemotactic response to the formylated peptide fMLP ([@B33]). The impact of 2-AG was blocked by the CB~2~ antagonist SR144528. Another study found that 2-AG and AEA do not induce neutrophil migration *in vitro* ([@B10]). However, 2-AG can stimulate other functions of human neutrophils, such as bioactive lipid synthesis, antimicrobial peptide release and oxidative burst ([@B11]). Importantly, these effects were shown to be CB~2~-independent, underscoring the importance of endocannabinoid metabolites in the regulation of neutrophil functions.

Endocannabinoids have also been implicated in eosinophil recruitment. Eosinophils are granulocytes that are found in minimal numbers in the blood of healthy individuals, but their levels are elevated in allergic diseases such as atopic dermatitis and asthma, or in parasitic infections. Their recruitment to the bronchial tissue and the airways is a hallmark of asthma and they actively participate in the onset and persistence of a chronic inflammatory state. As mentioned in Section "The Cannabinoid Receptors and the Lungs," human eosinophils strongly express the CB~2~ receptor, making them highly responsive to cannabinoids. In this respect, 2-AG was found to be a chemoattractant for human primary eosinophils *in vitro* ([@B47]; [@B30]; [@B34]). Noteworthy, the eosinophil differentiation factor and priming agent IL-5 greatly potentiates the effect of 2-AG ([@B34]). Furthermore, the CB~2~ receptor agonist JWH133 primed the response of eosinophils toward other chemoattractants ([@B17]). Although the principle of 2-AG-induced migration of eosinophils was confirmed *in vivo* in a murine model of dermatitis ([@B48]), the important impact that this could have on eosinophil migration to the lungs in asthmatic subjects remains to be defined. Of note, there have been two distinct case reports of individuals who developed an eosinophilic pneumonia following marijuana consumption ([@B35]; [@B43]) suggesting that cannabinoids could promote and/or induce an excessive recruitment of eosinophils to the lungs in humans.

Impact Of Cannabinoids On Host Defense *In Vivo*
================================================

Evidence from Animal Models
---------------------------

Given how cannabinoids can modulate immune cell functions (as detailed in Section "Impact of Cannabinoids on Acute Lung Inflammation"), it is likely that they have an impact on host defense to various pathogens. In this respect, murine models of lung infection were used to assess the involvement of cannabinoids in immunity against viruses and bacteria. **Table [1](#T1){ref-type="table"}** summarizes the data obtained from animal models of pulmonary infection. Noteworthy, the administration of cannabinoids in these protocols was never in the form of cannabis smoking, but rather as the direct administration of cannabinoids. These studies all point to the conclusion that the administration of plant-derived or synthetic cannabinoids impairs pathogen clearance and in certain cases, increases mortality. Of note, one study used cannabinoid receptor-deficient mice in their model of influenza infection, underscoring the involvement of cannabinoid receptors in the detrimental effects of Δ^9^-THC on lung immunity ([@B27]).

###### 

Impact of cannabinoids on pulmonary host defense in mouse models and humans.

  Treatment              Dose (administration route)   Model (species)                              Effects                                                     Reference
  ---------------------- ----------------------------- -------------------------------------------- ----------------------------------------------------------- ----------------
  Δ^9^-THC               25--75 mg/kg (oral gavage)    Influenza A/PR/8/34 infection (mouse)        ↑ Viral hemagglutinin 1 mRNA                                [@B5]
                                                                                                    ↓ CD4+ and CD8+ cells in BALF                               
                                                                                                    ↓ Macrophages in BALF                                       
                         75 mg/kg (oral gavage)                                                     ↓ IFN-γ-producing CD4+ cells                                [@B26]
                                                                                                    ↓ IL-17-producing NK cells                                  
                                                                                                    ↓ Antigen-presenting cells and inflammatory myeloid cells   
                                                                                                                                                                
                         8 mg/kg (i.v.)                *Legionella pneumophila* infection (mouse)   ↑ Mortality                                                 [@B31]; [@B62]
                                                                                                    ↑ Bacterial load in lungs                                   
                                                                                                    ↑ Serum levels of acute-phase cytokines                     
                                                                                                                                                                
                                                                                                    Shift from Th1 to Th2 immunity                              [@B44]
                                                                                                                                                                
  CBN                    6 mg/kg (i.v.)                *Legionella pneumophila* infection (mouse)   ↑ Mortality                                                 [@B62]
                                                                                                                                                                
                                                                                                    ↑ Bacterial load in lungs                                   
  CBD                    8-16 mg/kg (i.v.)             *Legionella pneumophila* infection (mouse)   No significant effects on mortality or bacterial load       [@B62]
                                                                                                                                                                
  CP55,940               6 mg/kg (i.v.)                *Legionella pneumophila* infection (mouse)   ↑ Mortality                                                 [@B62]
                                                                                                                                                                
                                                                                                    ↑ Bacterial load in lungs                                   
  CB~1~^-/-^CB~2~^-/-^   n/a                           Influenza A/PR/8/34 infection (mouse)        ↑ Pro-inflammatory mediator mRNA                            [@B27]
                                                                                                    ↑ T cell activation                                         
                                                                                                    ↑ IL-17 and IFN-γ production by NK cells and T cells        
                                                                                                    ↑ APC maturation                                            

BALF, bronchoalveolar lavage fluid; CBD, cannabidiol; CBN, cannabinol; NK, natural killer; APC, antigen presenting cells; i.v., intravenous.

Impact of Cannabinoids on Acute Lung Inflammation
=================================================

Acute lung injury (ALI) is characterized by a disruption of the vascular endothelium and the alveolar epithelium. There are numerous causes for ALI, including sepsis, pneumonia, aspiration of gastric contents, toxic gas inhalation, trauma and blood transfusion. At the cellular level, ALI causes the loss of alveolar--capillary membrane integrity, excessive neutrophil transmigration, and the release of pro-inflammatory mediators ([@B25]). Endotoxins such as LPS are often used to induce acute lung inflammation in animals, as this results in a pulmonary edema and neutrophilia mimicking human ALI. The impact of endocannabinoids, cannabinoids and even synthetic CB receptor agonists has been studied in these animal models of ALI. **Table [2](#T2){ref-type="table"}** summarizes the effects of cannabinoid treatment on the disease, which are, in most cases, beneficial. One study found that cannabidiol treatment worsens LPS-induced ALI ([@B28]), contradicting previous studies that showed the opposite (**Table [2](#T2){ref-type="table"}**). However, the route of administration of CBD was not consistent from one study to the other (oral gavage vs. intraperitoneal), possibly accounting for the different impact observed. Of note, a study by [@B13] used the monoacylglycerol lipase inhibitor JZL184 to increase 2-AG levels in the lungs of ALI mice, which resulted in an attenuation of ALI. Of note, CB~1~ and CB~2~ receptor antagonists partially blocked the impact of JZL184, indicating that other mechanisms are possibly involved in the effect of JZL184. Given that JZL184 can prevent the 2-AG-induced LTB~4~ biosynthesis by neutrophils as well as prostaglandin synthesis in the murine lung ([@B10]; [@B46]), it is possible that the effect of JZL184 implicates not only the activation of cannabinoid receptors but also a decrease in the synthesis of several eicosanoids. Nevertheless, the positive impact that this approach had on lung damage and inflammation underscores the potential of such pathway modulation strategies in ALI therapy development.

###### 

Impact of cannabinoids on pulmonary inflammation.

  Treatment               Dose (administration route)   Model (species)                                 Effects                               Reference
  ----------------------- ----------------------------- ----------------------------------------------- ------------------------------------- ----------------
  **ANTI-INFLAMMATORY**                                                                                                                       
  Δ^9^-THC                0.83 mg/kg (i.n.)             LPS-induced lung inflammation (mouse)           ↓ Neutrophils in BALF                 [@B4]
                                                                                                                                              
                                                                                                        ↓ TNF-α                               
                          20 mg/kg (i.p.)               Endotoxin B-induced lung inflammation (mouse)   ↓ Mortality                           [@B51]
                                                                                                        ↑ Airway resistance                   
                                                                                                        ↓ Vascular leak                       
                                                                                                        ↓ Leukocyte infiltration              
                                                                                                        ↓ Pro-inflammatory cytokines          
                                                                                                                                              
  WIN55,212-2             3.9 μg/kg (i.n.)              LPS-induced lung inflammation (mouse)           ↓ Neutrophils in BALF                 [@B4]
                                                                                                        ↓ TNF-α                               
                                                                                                                                              
  AEA                     26.1 ng/kg (i.n.)             LPS-induced lung inflammation (mouse)           ↓ Neutrophils in BALF                 [@B4]
                                                                                                        ↓ TNF-α                               
                                                                                                                                              
  CBD                     20-80 mg/kg (i.p.)            LPS-induced lung inflammation (mouse)           ↑ Lung function                       [@B53]; [@B52]
                                                                                                        ↓ Leukocyte recruitment               
                                                                                                        ↓ Pro-inflammatory cytokines          
                                                                                                        ↓ Myeloperoxidase                     
                                                                                                                                              
  JWH133                  1 mg/kg (i.p.)                Neurogenic pulmonary edema (rat)                ↓ Mortality                           [@B18]
                                                                                                        ↓ Myeloperoxidase                     
                                                                                                                                              
                          5--20 mg/kg (i.p.)            Paraquat-induced lung injury (rat)              ↓ Pulmonary edema                     [@B36]
                                                                                                        ↓ Lung damage                         
                                                                                                        ↓ Neutrophil infiltration             
                                                                                                                                              
  JZL184                  16 mg/kg (i.p.)               LPS-induced acute lung injury (mouse)           ↓ Leukocyte recruitment               [@B13]
                                                                                                        ↓ Lung damage                         
                                                                                                        ↓ Pro-inflammatory cytokines          
                                                                                                                                              
                                                                                                                                              
  **PRO-INFLAMMATORY**                                                                                                                        
                                                                                                                                              
  CBD                     75 mg/kg (oral gavage)        LPS-induced lung inflammation (mouse)           ↑ Inflammatory cell infiltration      [@B28]
                                                                                                        ↑ LPS-induced pulmonary lesions       
                                                                                                        ↑ TNF-α, IL-6, IL-23 and G-CSF mRNA   

G-CSF, granulocyte-colony stimulating factor; i.n., intranasal; i.p., intraperitoneal.

Conclusion and Perspectives
===========================

Initial studies unraveled that cannabis smoking has deleterious effects on lung function and inflammation, some of which are not caused by tobacco smoking. Of note, cannabinoids are involved in many of these effects. More recently, new tools and animal models indicate that the downregulation of immune cell functions by cannabinoids/endocananbinoids could dampen pulmonary inflammation to such an extent that it could diminish host defense. Thus, it becomes urgent to revisit the impact of cannabis smoking, cannabinoids and endocananbinoids on lung damages and pulmonary inflammation with more recent molecular and pharmacological tools. In addition, it is unclear to which extent the data obtained in animal models are translatable to humans. In that regard, additional studies should be undertaken to better decipher the impact of cannabis smoking and/or administration on human lung integrity and functions as well as to delineate if targeting endocannabinoids might provide new or complementary benefits compared to cannabinoids. Given that some of the anti-inflammatory effects of endocannabinoids are mediated by their metabolites, the modulation of endocannabinoid metabolic pathways might prove itself a better alternative to increase the beneficial effects of the cannabinoid system while limiting the detrimental ones.
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**Chemical names**: JWH015 = (2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone, CP55,940 = (--)-*Cis*-3-\[2-hydroxy-4-(1,1-dimethylheptyl)phenyl\]-*trans*-4-(3-hydroxypropyl)cyclohexanol, JWH133 = (6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetra-hydro-6,6,9-trimethyl-6H-dibenzo\[b,d\]pyran, JZL184 = 4-\[Bis(1,3-benzodioxol-5-yl)hydroxy-methyl\]-1-piperidinecarboxylic acid 4-nitrophenyl ester, SR144528 = 5-(4-chloro-3-methyl-phenyl)-1-\[(4-methylphenyl)methyl\]-*N*-\[(1S,2S,4R)-1,3,3-trimethylbicyclo\[2.2.1\]hept-2-yl\]-1H-pyrazole-3-carboxamide, WIN55,212-2 = \[(3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo\[1,2,3-de\]-1,4-benzoxazin-6-yl\]-1-naphthalenyl-methanone, monomethanesulfonate.
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